VirExit Technologies Inc (VXIT)

[beer$$money]

$VXIT Yes both PR's just a big promise of more of elephant poo.

From the Tuesday, 13 May 2025 11:15 AM PR JK wants you to believe In a decisive strategic initiative designed to maximize shareholder returns, VirExit has canceled 55,555,556 shares through the termination of its previous arrangement with Early Ventures Group.

But WTF the Annual Report August 31, 2024 Financial Statements for 08/31/2024 states: In September 2024, Early Ventures Group made the decision to terminate this Joint Venture, and the 55,555,556 common stock shares were returned to the Company.

Also, you know how you can tell if JK is lying: His lips are moving.

So why did , Early Ventures Group make the decision to terminate this Joint Venture:

Remember these are just a small fraction of what is stated in
THE MATTER OF DETERMINING Whether there has been a violation of the Securities Act of Washington by:
James Katzaroff, VirExit Technologies, Inc., Globestar Therapeutics Corporation,

https://dfi.wa.gov/sites/default/files/documents/securities-orders/S-23-3528-24-SO01.pdf

In February of 2021, James Katzaroff offered and sold stock in two Washington companies, VirExit Technologies and GSTC, through unregistered private placements. Katzaroff raised approximately $500,000 for each company.
Katzaroff made multiple material misrepresentations and omissions to investors.

During the period where Katzaroff spent the investor funds, there are no discernable payments for product development or product procurement, nor has Katzaroff or VirExit provided the Division with any contracts or communications from manufacturers or other documents indicating business activity.

Katzaroff failed to disclose to at least three investors the risk of investing in VirExit.

Katzaroff misrepresented to at least three investors how investments on the over-the-counter
(“OTC”) market work.

Katzaroff failed to disclose that at least 85% of the raised funds were spent on payments to Blankenship for the purchase of GSTC, marketing, and payments to Katzaroff himself.

James Katzaroff, VirExit Technologies, Inc. and GlobeStar Therapeutics Corporation violated RCW 21.20.010, the anti-fraud section of the Securities Act of Washington, by making untrue statements of material fact and/or omitting to state material facts